Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3 Evaxion will host a conference call and webcast to discuss the agreement on ...

Evaxion Biotech shares gained roughly 17% in early trade on Thursday after the company announced an expansion of its vaccine development collaboration with MSD (NYSE:MRK) (tradename of Merck & Co ...

MSD obtains a Non-Exclusive License for Cyprumed’s delivery technology to develop oral peptide therapeutics Cyprumed will be eligible to receive up to $493 million in upfront, development ...

Under the terms of the agreement, PeptiDream will receive an upfront payment from MSD and be eligible for payments based on the achievement of specified development, regulatory, and commercial ...

Evaxion and MSD have been collaborating on EVX-B3 since 2023. Also in 2023, MSD, through its Global Health Innovation Fund (MGHIF), led a private placement round of financing for Evaxion to become ...

Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3Evaxion will host a conference call and webcast to discuss the agreement on ...